Claim Missing Document
Check
Articles

Found 2 Documents
Search

Efektivitas Ekstrak Kaempferia Galanga Terhadap Proses Penyembuhan Luka Renni Yuniati; Farah Chilwa Hidayati; Muhammad Auzinal Haq; Muhammad Ahda Sabila
Jurnal Impresi Indonesia Vol. 4 No. 6 (2025): Jurnal Impresi Indonesia
Publisher : Riviera Publishing

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Wound healing is a complex biological process that involves various stages of tissue regeneration. In the world of traditional medicine, Kaempferia galanga is widely known for its content of active compounds that have anti-inflammatory, antimicrobial, and antioxidant properties. This study aims to systematically review the adjuvant therapeutic efficacy of Kaempferia galanga rhizome extract in accelerating wound healing based on published experimental studies. This research method uses a systematic literature review approach by examining articles from national and international scientific databases over the past ten years. The results of the study show that the administration of Kaempferia galanga extract can increase re-epithelialization, reduce inflammatory response, and accelerate the formation of granulated tissue. Overall, rhizome-based adjuvant therapy Kaempferia galanga has the potential to be an alternative in the development of more natural and safe wound-healing agents. The conclusions of this study emphasize the importance of further exploration through clinical trials to ensure the effectiveness and safety of its long-term use in medical practice.
Leprosy in the Era of Zero-Leprosy Targets: Pathobiology, Clinical Care, Prevention, and Implementation Priorities Renni Yuniati; Farah Chilwa Hidayati; Muhammad Auzi’nal Haq
Al Makki Health Informatics Journal Vol. 4 No. 1 (2026): Al Makki Health Informatics Journal
Publisher : Al Makki Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.57185/a3dk2q86

Abstract

Leprosy (Hansen disease) is a chronic infectious disease caused predominantly by Mycobacterium leprae and, in a smaller number of cases, Mycobacterium lepromatosis. Although multidrug therapy (MDT) has made leprosy curable and has markedly reduced prevalence, approximately 200,000 new cases are reported annually, with Brazil, India, and Indonesia carrying the largest burdens. This narrative review synthesizes World Health Organization guidance and peer-reviewed literature published between 2018 and 2026, with seminal older sources retained, identified in PubMed, Scopus, WHO IRIS, Google Scholar, and the Indonesian databases Garuda and SINTA, to map the distance between biomedical cure and programme-level elimination. Clinical expression is heterogeneous because host immunity determines the balance between bacillary control, inflammation, and nerve injury. Diagnosis remains primarily clinical and is anchored by three cardinal signs. The main therapeutic regimen is rifampicin, dapsone, and clofazimine for 6 months in paucibacillary disease and 12 months in multibacillary disease. However, MDT alone is insufficient to interrupt transmission or prevent disability. Contact screening, single-dose rifampicin post-exposure prophylaxis, active case finding, early recognition of neuritis and leprosy reactions, rehabilitation, and stigma reduction are necessary components of a contemporary control programme. Its distinctive contribution is an explicit Indonesia-focused implementation perspective linking national epidemiological data, detection delay, and stigma to measurable programme indicators. Priority research areas include field-ready diagnostics, surveillance of antimicrobial resistance, predictive biomarkers for nerve injury, and delivery models that integrate affected persons and communities into prevention and care.